Fighting "Experimental" Insurance Denials: FDA Approval, Compendia, and Clinical Trials

One of the most frustrating — and often incorrect — insurance denials is the label "experimental" or "investigational." Insurers use these terms to deny treatments that are, in reality, widely used, scientifically supported, and recommended by the nation's leading medical experts. Understanding how to challenge an experimental denial requires knowing exactly how most insurance policies define "not experimental" — and then proving your treatment meets those definitions.

How Insurance Policies Define "Experimental"

Most health insurance policies exclude coverage for treatments that are "experimental, investigational, or unproven." The policy typically defines these terms using criteria such as:

1. FDA approval for the specific indication
2. Listing in a recognized drug compendium for the diagnosis being treated
3. Support in peer-reviewed medical literature
4. Endorsement in a clinical practice guideline from a major professional society
5. Whether the treatment has emerged from Phase III clinical trials

The key insight: most policies use these criteria as a definition of what is not experimental. If your treatment meets any or all of these criteria, it is — by your policy's own definition — covered. Your appeal should demonstrate, criterion by criterion, that the treatment is established rather than experimental.

Criterion 1: FDA Approval

FDA approval for your specific indication is the clearest and most definitive evidence that a treatment is not experimental. The FDA approves drugs and devices only after substantial evidence of safety and efficacy — often hundreds of millions of dollars and years of clinical trials.

If your treatment is FDA-approved for your specific condition, state this prominently in your appeal: "The FDA approved [drug/device] for [indication] on [date]. FDA approval is defined in most coverage policies as evidence that a treatment is not experimental. The attached FDA prescribing label confirms approval for this indication."

Off-label use: A more complex situation arises when your treatment is FDA-approved for a different condition than yours. Off-label prescribing is common and legal, and many insurance policies explicitly cover off-label use when supported by compendia or peer-reviewed literature. Check your policy — many explicitly state that off-label use is covered if listed in AHFS, Micromedex, or another compendium.

Criterion 2: Drug Compendia

For pharmaceuticals, most insurance policies — and many state laws — require coverage of a drug if it is listed in one of several recognized drug compendia for the diagnosis at issue. The major compendia are:

• AHFS Drug Information (American Hospital Formulary Service) — the gold standard, published by the American Society of Health-System Pharmacists
• Micromedex (IBM Watson Health) — widely accepted, includes evidence ratings
• Lexi-Drugs (Wolters Kluwer) — commonly used in clinical practice
• DrugDex (part of Micromedex) — frequently cited in state statutes
• Clinical Pharmacology — another widely referenced compendium

If your medication is listed in any of these compendia for your specific indication, you have strong grounds to challenge an experimental denial.

What to do: Ask your pharmacist or prescribing physician to check the relevant compendium listing and provide you with the specific compendia entry showing the drug is listed for your diagnosis. Your physician may have institutional access to these databases. Reference the compendium name, version/date, and the indication listed.

Federal law (the Social Security Act § 1861(t)(2)(B)) requires Medicare to cover off-label drug uses listed in these compendia, and most state laws that address off-label coverage similarly reference these compendia.

Criterion 3: Clinical Practice Guidelines

A recommendation from a major professional medical society in a clinical practice guideline is powerful evidence that a treatment is not experimental. Major guideline organizations include:

• NCCN (National Comprehensive Cancer Network): NCCN Guidelines are the most widely cited in oncology. Category 1 evidence (based on high-level evidence with uniform consensus) is particularly compelling. Category 2A (lower-level evidence with uniform consensus) is also typically accepted by insurers.
• ACC/AHA: For cardiovascular conditions
• American Society of Clinical Oncology (ASCO)
• Infectious Diseases Society of America (IDSA)
• American Academy of Neurology (AAN)
• American College of Rheumatology (ACR)
• Endocrine Society, ACR, AAOS, AAP — for their respective specialties

Include the specific guideline name, version, and recommendation. For NCCN: access NCCN.org and print the relevant guideline page. Some guidelines require a free registration to access. Alternatively, ask your oncologist or specialist to provide the relevant guideline excerpt.

Criterion 4: Peer-Reviewed Clinical Literature

As detailed in a companion guide, peer-reviewed published studies — especially systematic reviews, meta-analyses, and Phase III RCTs — are strong evidence that a treatment is established rather than experimental.

For an experimental denial appeal, focus on studies that:

• Are published in high-impact journals (NEJM, JAMA, Lancet, major specialty journals)
• Show efficacy for your specific diagnosis
• Have been conducted in Phase III (or later) trials
• Have been replicated by independent research groups

Criterion 5: Clinical Trial Participation

If a treatment is still under clinical investigation but a qualifying clinical trial is available, most insurance policies and all ACA-compliant plans are required to cover the routine costs of clinical trial participation. The ACA (42 USC § 300gg-8) requires coverage of:

• Routine patient costs of care (doctor visits, tests, etc.) that would otherwise be covered if you weren't in a trial
• Items and services required solely for the clinical trial

The trial itself must be a "qualifying" clinical trial — Phase I, II, or III trials for treating cancer or life-threatening diseases, conducted by federal agencies, NIH-funded entities, or IND-approved sponsors.

If the "experimental" treatment you need is available in a clinical trial, this is worth exploring both as a coverage strategy and as a medical option.

Building Your Experimental Treatment Appeal

Structure your appeal to address each applicable criterion:

1. State the denial reason and the policy definition. "The denial cites the treatment as experimental. My policy defines 'not experimental' as... The following evidence demonstrates that [treatment] meets this definition."

2. Address FDA approval. Is it FDA-approved for your indication? If so, state this and attach the prescribing label or FDA drug database printout.

3. Address compendia listing. Is it listed in AHFS, Micromedex, or another recognized compendium for your diagnosis? If so, reference the compendium and indication.

4. Address clinical guidelines. Is it recommended in NCCN, ACC/AHA, or another major guideline? If so, cite the specific recommendation category.

5. Address peer-reviewed literature. Are there published Phase II or Phase III studies or meta-analyses supporting efficacy? Cite the key studies.

6. Request External Independent Review: Complete Guide" class="auto-link">external review. If the internal appeal is denied, the ACA requires that experimental treatment denials based on clinical evidence be eligible for external independent review. Exercise this right.

Fight Back With ClaimBack

An "experimental" denial is rarely the end of the road. ClaimBack helps you build an appeal that systematically addresses each criterion in your policy's definition of "not experimental" — turning the insurer's own language against an improper denial.

Start your appeal at ClaimBack

Related Reading

• How to Use Peer-Reviewed Medical Literature in Your Appeal
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal